Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR–ABL inhibitors
暂无分享,去创建一个
T. Naoe | S. Mizuno | J. Hiraga | A. Abe | Y. Minami | K. Kitamura | M. Sawa | Y. Inagaki | K. Miyamura | M. Minami | K. Ymamoto